MX2013001836A - Proteina de fusion de fc recombinante del quinto dominio tipo iii de fibronectina de ddc. - Google Patents

Proteina de fusion de fc recombinante del quinto dominio tipo iii de fibronectina de ddc.

Info

Publication number
MX2013001836A
MX2013001836A MX2013001836A MX2013001836A MX2013001836A MX 2013001836 A MX2013001836 A MX 2013001836A MX 2013001836 A MX2013001836 A MX 2013001836A MX 2013001836 A MX2013001836 A MX 2013001836A MX 2013001836 A MX2013001836 A MX 2013001836A
Authority
MX
Mexico
Prior art keywords
dcc
recombinant
fusion protein
type iii
fibronectin type
Prior art date
Application number
MX2013001836A
Other languages
English (en)
Inventor
Patrick Mehlen
Christian Klein
Erhard Kopetzki
Gerhard Niederfellner
Agnes Bernet
Celine Delloye-Bourgeois
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2013001836A publication Critical patent/MX2013001836A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

La presente invención es concerniente con proteínas de fusión de DCC, moléculas de ácido nucleico que codifican la proteína de fusión de DCC, también como métodos para su producción y su uso en el tratamiento de cáncer, tal como cáncer colorectal, NSCLC y cáncer de pecho metastático. La presente invención también es concerniente con métodos para el tratamiento de cáncer, tal como cáncer colorectal, NSCLC y cáncer de pecho metastático al administración proteínas de fusión de DCC.
MX2013001836A 2010-08-26 2011-08-26 Proteina de fusion de fc recombinante del quinto dominio tipo iii de fibronectina de ddc. MX2013001836A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10290459 2010-08-26
PCT/EP2011/064733 WO2012025618A1 (en) 2010-08-26 2011-08-26 Recombinant fc-fusion protein of the fifth fibronectin type iii domain of dcc

Publications (1)

Publication Number Publication Date
MX2013001836A true MX2013001836A (es) 2013-07-29

Family

ID=44004886

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001836A MX2013001836A (es) 2010-08-26 2011-08-26 Proteina de fusion de fc recombinante del quinto dominio tipo iii de fibronectina de ddc.

Country Status (10)

Country Link
US (1) US20130336972A1 (es)
EP (1) EP2609430A1 (es)
JP (1) JP2013538051A (es)
KR (1) KR20140004632A (es)
CN (1) CN103339507A (es)
BR (1) BR112013004358A2 (es)
CA (1) CA2807273A1 (es)
MX (1) MX2013001836A (es)
RU (1) RU2013111675A (es)
WO (1) WO2012025618A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2708241A1 (en) 2012-09-12 2014-03-19 Netris Pharma Recombinant Fc-fusion protein of the two Immunoglobulin domains of UNC5
EP2708231A1 (en) 2012-09-12 2014-03-19 Netris Pharma Combined treatment with netrin-1 interfering drug and chemotherapeutic drug
US10654933B2 (en) * 2013-12-27 2020-05-19 Chugai Seiyaku Kabushiki Kaisha Method for purifying antibody having low isoelectric point
EP2893939A1 (en) 2014-01-10 2015-07-15 Netris Pharma Anti-netrin-1 antibody
AR106543A1 (es) 2015-11-02 2018-01-24 Netris Pharma Terapia de combinación de agente neutralizante de ntn1 con fármacos que inhiben el control epigenético
CN110291105B (zh) 2017-01-05 2024-03-01 奈特里斯药物公司 导蛋白-1干扰药物和免疫检查点抑制剂药物的组合治疗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
US5057604A (en) * 1988-08-03 1991-10-15 Washington University Novel monoclonal antibodies
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
PL1989546T3 (pl) * 2006-02-28 2017-03-31 Centre National De La Recherche Scientifique (Cnrs) Poszukiwanie związków o działaniu przeciwnowotworowym z zastosowaniem aktywności netryny-1

Also Published As

Publication number Publication date
JP2013538051A (ja) 2013-10-10
CA2807273A1 (en) 2012-03-01
US20130336972A1 (en) 2013-12-19
WO2012025618A1 (en) 2012-03-01
CN103339507A (zh) 2013-10-02
KR20140004632A (ko) 2014-01-13
EP2609430A1 (en) 2013-07-03
BR112013004358A2 (pt) 2017-06-27
RU2013111675A (ru) 2014-10-10

Similar Documents

Publication Publication Date Title
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
PH12019500441A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
MX346923B (es) Genes y proteinas para sintesis de alcanoil-coa.
EA201590998A1 (ru) СВЯЗЫВАЮЩИЕСЯ С EGFR И c-Met МОЛЕКУЛЫ С ДОМЕНАМИ ФИБРОНЕКТИНА ТИПА III
MX2013004761A (es) Nuevas moleculas de union al receptor del factor de crecimiento epidermico (egfr) e inmunoconjugados de estas.
NZ603570A (en) Biological materials related to her3
TN2012000144A1 (en) Dll4-binding molecules
MY171038A (en) Bispecific antigen binding molecules
MX353813B (es) Moleculas de union a vegf.
MY181086A (en) Anti-egfr antibodies and uses thereof
MX2013001836A (es) Proteina de fusion de fc recombinante del quinto dominio tipo iii de fibronectina de ddc.
MX338981B (es) Proteina de fusion robo1-fc y sus uso en el tratamiento de tumores.
MX2014011583A (es) Metodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing.
MX2011011075A (es) Anticuerpos especificos para cadherina-17.
FI20115328A0 (fi) Uusia kutinaaseja, niiden tuottaminen ja käytöt
EA201391423A1 (ru) Антитела к ассоциированному с почками антигену 1 и их антигенсвязывающие фрагменты
MX2021002985A (es) Polipeptidos del factor vii de accion corta.
SG191060A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
GB201105584D0 (en) Cancer methods
WO2011085134A8 (en) Methods and compositions for the diagnosis, prognosis and treatment of cancer
WO2013109190A3 (en) Cho-gmt recombinant protein expression
EA202090841A2 (ru) СВЯЗЫВАЮЩИЕСЯ С EGFR И c-Met МОЛЕКУЛЫ С ДОМЕНАМИ ФИБРОНЕКТИНА ТИПА III